100% de satisfacción garantizada Inmediatamente disponible después del pago Tanto en línea como en PDF No estas atado a nada
logo-home
Buscado previamente por ti
Buscado previamente por ti
logo
Samenvatting - MIN18 Hemato-oncology: From concept to cure (MIN18) Summary $12.88
Añadir al carrito
Navegar rápidamente a
Vista previa
  2.  
  3. Radboud Universiteit Nijmegen (RU)
  4.  
  5. MIN18 Hemato-oncology: From concept to cure (MIN18)

Resumen

Samenvatting - MIN18 Hemato-oncology: From concept to cure (MIN18) Summary
 1 veces vendidas
  • Grado
  • MIN18 Hemato-oncology: From concept to cure (MIN18)
  • Institución
  • Radboud Universiteit Nijmegen (RU)

Deze samenvatting bevat alle onderwerpen behandeld tijdens minor 18 (stem cell biology, clonal evolution, pathogenesis, leukemic transformation, acute myeloid leukemia, flow cytometry, autologous/allogeneic transplantation, myelo proliferative diseases, (chronic myeloid leukkemia, essential thrombo...

[Mostrar más]

Vista previa 4 fuera de 50  páginas

Información del documento

  • 15 de octubre de 2024
  • 50
  • 2023/2024
  • Resumen

Temas

  • hemato oncology
  • stem cell biology
  • cml
  • b cell development
  • lymphoma
  • plasma cell dyscrasia
  • multiple myeloma
  • aml
  • autologous transplantation
  • allogeneic transplantation
  • myelo proliferative diseases

Escuela, estudio y materia

  • Radboud Universiteit Nijmegen (RU)
  • Biomedische Wetenschappen
  • MIN18 Hemato-oncology: From concept to cure (MIN18)
Todos documentos para esta materia (1)

Vendedor

avatar-seller
StudentRU07

Vista previa del contenido

Hemato-Oncology: From Concept to Cure




HEMATO-ONCOLOGY: FROM
CONCEPT TO CURE
Minor 18




Opleiding: Bachelor biomedische wetenschappen
Onderwijsinstelling: Radboud




1

, Hemato-Oncology: From Concept to Cure




Index
Stem Cell Biology, Clonal Evolution, Pathogenesis and Leukemic Transformation.............................4
Stem Cell Biology...................................................................................................................................................4
Leukemic transformation......................................................................................................................................4
Apoptosis...............................................................................................................................................................5
DNA methylation...................................................................................................................................................6
Ubiquitination........................................................................................................................................................6
Example p53....................................................................................................................................................7

Acute Myeloid Leukemia...................................................................................................................7
Pathogenesis.........................................................................................................................................................7
Clinical presentation..............................................................................................................................................7
Diagnosis................................................................................................................................................................8
Diagnostics.............................................................................................................................................................9
Flow cytometry................................................................................................................................................9

Cytogenetics..................................................................................................................................................10

Treatment......................................................................................................................................................10

Autologous transplantation..........................................................................................................................12

Allogeneic transplantation............................................................................................................................12

Myelo Proliferative Diseases...........................................................................................................15
Chronic myeloid leukemia...................................................................................................................................16
Clinical presentation of CML.........................................................................................................................16

Essential thrombocythemia (ET).........................................................................................................................17
Symptoms......................................................................................................................................................17

Treatment......................................................................................................................................................17

Polycythemia vera...............................................................................................................................................17
Symptoms......................................................................................................................................................17

Treatment......................................................................................................................................................17

Primary myelofibrosis..........................................................................................................................................17
Symptoms......................................................................................................................................................18

Treatment......................................................................................................................................................18

B-cell development..........................................................................................................................19

Lymphoma.......................................................................................................................................20
Diagnostics..........................................................................................................................................................20
Pathology.......................................................................................................................................................21
2

, Hemato-Oncology: From Concept to Cure



Ann Arbor staging..........................................................................................................................................21

Follicular lymphoma............................................................................................................................................21
Pathogenesis.................................................................................................................................................21

Diagnosis.......................................................................................................................................................21

Disease course...............................................................................................................................................22

Therapeutic options......................................................................................................................................22

Diffuse Large B-cell Lymphoma (DLBCL)..............................................................................................................22
Pathogenesis.................................................................................................................................................22

Diagnosis.......................................................................................................................................................23

Disease course...............................................................................................................................................23

Therapeutic options......................................................................................................................................23

Plasma Cell Dyscrasia – Multiple myeloma......................................................................................24
Pathogenesis.......................................................................................................................................................24
Symptoms............................................................................................................................................................24
Diagnose..............................................................................................................................................................25
Immunology..................................................................................................................................................25

Risk assessment.............................................................................................................................................27

Treatment............................................................................................................................................................27

Appendix.........................................................................................................................................29
IVT – GVT Allogeneic stem cell transplantation..................................................................................................29
IVT – GVT Stem cell biology, clonal evolution, pathogenesis and leukemic transformation.............................31
IVT – GVT Acute Myeloid Leukemia – Diagnostics (flow cytometry)..................................................................33
IVT – GVT Allogeneic stem cell transplantation - Immunology and GVHD.........................................................35
IVT – GVT Cellular Immunotherapy – T-cells, Dendritic Cells and NK-cells.........................................................36
IVT – GVT Chronic Myeloid leukemia and primary Myelofibrosis – Clinical aspects and diagnostics................38
IVT – GVT Essential Thrombocytosis and Polycythaemia Vera and secondary myelofibrosis............................40
Formative exam AML and MPN..........................................................................................................................42
IVT – GVT Lymphoma & PDC – Clinical aspects...................................................................................................45
IVT – GVT Lymphoma & PDC – Therapeutic options...........................................................................................47
Formative exam lymphoma and plasma cell dyscrasia.......................................................................................49




3

, Hemato-Oncology: From Concept to Cure


Stem Cell Biology, Clonal Evolution, Pathogenesis and Leukemic Transformation
Stem Cell Biology
Blood cells are divided into three major groups:
 Red blood cells (erythrocytes), which provide oxygen transport. A deficiency of red blood cells leads to
anemia.
 White blood cells (leukocytes), which are responsible for defense against infections. These are divided
into five types, each with its own name and function. Each species has great variation in terms of
percentage and numbers:
 basophilic granulocytes <1%
 eosinophilic granulocytes 1-6%;
 neutrophilic granulocytes 40-75%
 lymphocytes 20-40%
 monocytes 2-10%.
 Platelets (thrombocytes), responsible for primary hemostasis or blood clotting

During their maturation, hematopoietic
cells express proteins on their cell
membrane (so-called CD markers) the
composition of these proteins depends on
the developmental stage the cell is in.
Hematopoietic stem cells express the
surface molecule CD34 on their cell
membrane. Matured blood cells are CD34
negative.

Characteristic of B cells is the expression of
CD20 on the cell membrane. T cells,
however, express CD4 and CD8.

Pleitropic growth factors: these are factors aimed at differentiation and already act on precursor or progenitor
cells, such as IL-3, for example.

Lineage-specific growth factors: are factors aimed at maturation, they
act on the more mature cells, such as G-CSF on neutrophilic
granulocytes and basophilic granulocytes and Epo on erythrocytes.

Leukemia results from the uncontrolled accumulation of primitive,
poorly differentiated blood cells, and is a consequence of the
accumulation of mutations in hematopoietic precursor cells. It seems
likely that mutations affecting at least two pathways are required for
the development of leukemia. One of these pathways regulates cell
accumulation; the second regulates hematopoietic differentiation.

Genes that are mutated in leukemia can be classified in four major biological groups:
 Growth factor receptors
 Signal transduction molecules
 Gene expression regulation
 Apoptosis

Leukemic transformation
Random mutations occur in our genome for instance by toxic agents, UV and mistakes in copying DNA during
cell division. Most of these mutations are biologically inactive and not harmful. Still they are passed on to all
daughter cells. These mutations are called passenger mutations. When, however a mutation occurs in a gene
that regulates the balance between proliferation and differentiation, the cell may acquire a growth advantage
leading to the expansion of a clone that harbors the mutation. These mutations are called driver mutations.
4

Los beneficios de comprar resúmenes en Stuvia estan en línea:

Garantiza la calidad de los comentarios

Garantiza la calidad de los comentarios

Compradores de Stuvia evaluaron más de 700.000 resúmenes. Así estas seguro que compras los mejores documentos!

Compra fácil y rápido

Compra fácil y rápido

Puedes pagar rápidamente y en una vez con iDeal, tarjeta de crédito o con tu crédito de Stuvia. Sin tener que hacerte miembro.

Enfócate en lo más importante

Enfócate en lo más importante

Tus compañeros escriben los resúmenes. Por eso tienes la seguridad que tienes un resumen actual y confiable. Así llegas a la conclusión rapidamente!

Preguntas frecuentes

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

100% de satisfacción garantizada: ¿Cómo funciona?

Nuestra garantía de satisfacción le asegura que siempre encontrará un documento de estudio a tu medida. Tu rellenas un formulario y nuestro equipo de atención al cliente se encarga del resto.

Who am I buying this summary from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller StudentRU07. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy this summary for $12.88. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

45,681 summaries were sold in the last 30 days

Founded in 2010, the go-to place to buy summaries for 15 years now

Empieza a vender

Vistos recientemente

Examen ·

(0)

NUR 254 ( LATEST 2024 / 2025 ) TEST 1 | QUESTIONS AND ANSWERS INCLUDED

Examen ·

(0)

PSYCH 3002 Research Methods Exam 2 Question and answers latest update

Examen ·

(0)

Air Assault Phase 1 Test Exam with Guaranteed Accurate Answers

Ensayo ·

(1)

Eindverslag Toolkit: Video-interactiebegeleiding Jaar 2 SPH/Social Work

Examen ·

(0)

Test Bank of Microeconomics 7th Edition Jeffrey M. Perlof|All Chapters|

Examen ·

(0)

BEST REVIEW HESI RN exit! 100% VERIFIED ANSWERS 2024/2025 ALREADY PASSED

Resumen ·

(0)

Examenvragen technische uitrusting en onderhoud recent (2020) + antwoorden

$12.88  1x  vendido
  • (0)
Añadir al carrito
Añadido